Pfizer Inc. today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective immediately. Cecile has served as interim Chief Financial Officer since August 16, 2026, steering the company’s financial operations, execution, and strategic planning.
Albert Bourla, CEO said in a release Tuesday: “Cecile is an exceptional finance leader who knows our company and industry deeply, and she has a proven track record of optimizing financial performance while fueling growth. Her more than 25 years of experience paired with her strategic vision will provide the financial rigor and focus this next chapter demands as we aim for meaningful growth. I’m confident she will help us execute with discipline and ambition as we work to deliver for our patients and shareholders.”
“I am honored to step into this role to continue positioning Pfizer for durable long-term growth and shareholder value creation,” said Cecile Guegan, Chief Financial Officer and Executive Vice President, Pfizer. “My focus remains on executing a disciplined approach to capital allocation while making targeted investments today to drive revenue growth later in the decade and beyond.”
Cecile will oversee all aspects of the Company’s financial management. She will lead every corporate finance function, including audit, treasury, investor relations, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.
Prior to stepping into the interim finance leadership role, Cecile was directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. In previous positions, Cecile served as a strategic partner to group presidents and chief commercial officers, led long-term forecasting for key product portfolios, led major enterprise acquisitions and integrations and co-led a strategic initiative to identify new sources of growth.
The new appointment comes as Pfizer reported third-quarter results on Tuesday that beat estimates and raised its full-year outlook, as demand for its newly launched and acquired products grows.
The company now expects full-year revenue of $62 billion to $64 billion, up from a previous outlook of $60.5 billion to $62.5 billion.
By CEO NA Editorial Staff
